Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Oct;34(5):681-694.
doi: 10.1007/s40259-020-00438-7.

Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials

Kristin K Jørgensen  1 , Guro L Goll  2 , Joe Sexton  2 , Nils Bolstad  3 , Inge C Olsen  4 , Øivind Asak  5 , Ingrid P Berset  6 , Ingrid M Blomgren  7 , Katrine Dvergsnes  8 , Jon Florholmen  9   10 , Svein O Frigstad  11   12 , Magne Henriksen  13 , Jon Hagfors  14 , Gert Huppertz-Hauss  15 , Espen A Haavardsholm  2   12 , Rolf A Klaasen  3 , Bjørn Moum  12   16 , Geir Noraberg  17 , Ulf Prestegård  18 , Jan H Rydning  19   20 , Liv Sagatun  21 , Kathrine A Seeberg  22 , Roald Torp  23 , Cecilia Vold  24 , David J Warren  3 , Carl M Ystrøm  25 , Knut E A Lundin  12   26   27 , Tore Kvien  2   12 , Jørgen Jahnsen  19   12
Affiliations
Randomized Controlled Trial

Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials

Kristin K Jørgensen et al. BioDrugs. 2020 Oct.

Abstract

Background: The NOR-SWITCH main and extension trials demonstrated that switching from originator to biosimilar infliximab (CT-P13) is efficacious and safe across six diseases. However, a subgroup analysis of Crohn's disease (CD) in the main trial displayed a close to significant difference favouring originator infliximab, and more scientific data have therefore been requested.

Objective: The aim was to assess treatment efficacy, safety, and immunogenicity in an explorative subgroup analysis in CD and ulcerative colitis (UC) in the NOR-SWITCH trials.

Patients and methods: The 52-week, randomised, non-inferiority, double-blind, multicentre, phase 4 NOR-SWITCH study was followed by a 26-week open extension trial where all patients received treatment with CT-P13. Treatment efficacy, safety, and immunogenicity in CD and UC were assessed throughout the 78-week study period.

Results: The main and extension trials included 155 and 93 patients with CD and 93 and 80 patients with UC, respectively. Demographic and baseline characteristics were comparable in both treatment arms within patient groups. There were no differences in the main and extension trials regarding changes in activity indices, C-reactive protein, faecal calprotectin, patient's and physician's global assessment of disease activity and patient-reported outcome measures in CD and UC. Moreover, comparable results were also demonstrated for trough serum levels, presence of anti-drug antibodies, and reported adverse events.

Conclusion: Efficacy, safety, and immunogenicity of both the originator and biosimilar infliximab were comparable in CD and UC in the NOR-SWITCH main and extension trials. These explorative subgroup analyses confirm that there are no significant concerns related to switching from originator infliximab to CT-P13 in CD and UC.

Trial registration: ClinicalTrials.gov, number NCT02148640.

PubMed Disclaimer

Conflict of interest statement

KKJ reports personal fees from Intercept, Norgine, and Celltrion. GLG reports personal fees from AbbVie, Biogen, Eli Lilly, MSD, Novartis, Pfizer, Roche, Sandoz, Orion Pharma, Celltrion, and Boehringer Ingelheim. NB reports personal fees received from Orion Pharma, Roche, Napp Pharmaceuticals, Pfizer, and Takeda. ICO reports grants from the Norwegian Ministry of Health and Care Services during the conduct of the study and personal fees from Pfizer. EAH reports grants from AbbVie, Pfizer, UCB, Roche, and MSD. IPB reports personal fees from AbbVie, MSD, Takeda, Hospira, and Ferring. KEAL reports grants from MSD and personal fees from Takeda, Orion, AbbVie, Pfizer, and MSD. JJ reports personal fees from MSD, AbbVie, Celltrion, Orion Pharma, Takeda, Napp Pharm, AstroPharma, Hikma, and Pfizer. TK reports grants from the Norwegian Ministry of Health and Care Services during the conduct of the study and personal fees from AbbVie, Biogen, BMS, Boehringer Ingelheim, Celltrion, Eli Lilly, Epirus, Janssen, Merck-Serono, MSD, Mundipharma, Novartis, Oktal, Orion Pharma, Hospira/Pfizer, Roche, Sandoz, and UCB Pharma. SOF reports personal fees from Takeda, Pharmacosmos, Tillotts, Janssen, Intercept, and Pfizer. The remaining authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Patient disposition in IBD in the NOR-SWITCH main and extension study. CD Crohn’s disease, IBD inflammatory bowel disease, IFX infliximab, PPS per-protocol set, UC ulcerative colitis. 1 Four CD patients withdrew consent, two CD and one UC patients had major change in immunosuppressive treatment, two CD patients were unblinded during the study, two CD patients developed adverse events, and one CD patient was excluded for other reasons. 2 Seven CD and four UC patients withdrew consent, two CD and five UC patients had major change in immunosuppressive treatment, two CD patients were unblinded during the study, one CD and two UC patients developed adverse events, three CD patients and one UC patient were excluded for other reasons
Fig. 2
Fig. 2
Secondary efficacy endpoints in Crohn’s disease from randomisation in main study (baseline/week 0) to study end (week 78), per-protocol set. IFX infliximab
Fig. 3
Fig. 3
Secondary efficacy endpoints in ulcerative colitis from randomisation in main study (baseline/week 0) to study end (week 78), per-protocol set. IFX infliximab
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kuek A, Hazleman BL, Ostor AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(978):251–260. doi: 10.1136/pgmj.2006.052688. - DOI - PMC - PubMed
    1. Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198–206. doi: 10.1136/annrheumdis-2012-202603. - DOI - PubMed
    1. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605–1612. doi: 10.1136/annrheumdis-2012-203091. - DOI - PMC - PubMed
    1. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–1620. doi: 10.1136/annrheumdis-2012-203090. - DOI - PMC - PubMed
    1. Billmeier U, Dieterich W, Neurath MF, Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol. 2016;22(42):9300–9313. doi: 10.3748/wjg.v22.i42.9300. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data